Medication info
Gardemet Tablet 100/500 mg

Gardemet Tablet 100/500 mg

Prescription medicationTabletOral
Ingredient · strength
Anagliptin›100mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
JW Pharmaceutical Corp.
Appearance
Pale yellow oblong film-coated tablet
Packaging
30 tablets (10 tablets/PTP packaging × 3), 60 tablets/bottle
Approval status
Active

MFDS item code 201600172 · Approved 2016.01.08 · Insurance code 644914130

Summary

Main use
Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The dose of this medicine should be adjusted according to efficacy and tolerability, without exceeding the maximum recommended daily doses of each ingredient: anagliptin 200mg and metformin 2000mg. The initial dose of this medicine is determined according to the patient's current treatment regimen. To reduce gastrointestinal adverse effects associated with metformin use, this medicine should be taken twice daily with meals, and the dose should be increased gradually. This medicine should be swallowed whole. 1. When adequate glycemic control cannot be achieved with metformin monotherapy The initial dose of this medicine is anagliptin 100mg twice daily (total daily dose of 200mg) and the patient's current dose of metformin, according to the patient's current treatment regimen; take 1 tablet of this medicine 100/500mg or 100/850mg or 100/1000mg twice daily. 2. Replacement of combination therapy with anagliptin and metformin When switching from combination therapy with anagliptin and metformin to this medicine, treatment may be started at the current doses of anagliptin and metformin.

Ingredients

Manufacturer
JW Pharmaceutical Corp.

Efficacy & effects

Improves glycemic control in adults with type 2 diabetes mellitus

View approved original text

This medication helps manage blood glucose levels in adults with type 2 diabetes that is not adequately controlled by diet and exercise alone, using a combination of anagliptin and metformin. It can enhance effectiveness when added to metformin monotherapy when blood glucose control is inadequate. It is also used for patients who are already using anagliptin and metformin together to switch to this medication, thereby improving blood glucose control and aiding diabetes management.

How to take

Adult dose

The dose of this medicine should be adjusted according to efficacy and tolerability, without exceeding the maximum recommended daily doses of each ingredient: anagliptin 200mg and metformin 2000mg. The initial dose of this medicine is determined according to the patient's current treatment regimen. To reduce gastrointestinal adverse effects associated with metformin use, this medicine should be taken twice daily with meals, and the dose should be increased gradually. This medicine should be swallowed whole. 1. When adequate glycemic control cannot be achieved with metformin monotherapy The initial dose of this medicine is anagliptin 100mg twice daily (total daily dose of 200mg) and the patient's current dose of metformin, according to the patient's current treatment regimen; take 1 tablet of this medicine 100/500mg or 100/850mg or 100/1000mg twice daily. 2. Replacement of combination therapy with anagliptin and metformin When switching from combination therapy with anagliptin and metformin to this medicine, treatment may be started at the current doses of anagliptin and metformin.

Precautions

This medication contains ingredients used for diabetes treatment that are anagliptin and metformin. When taking this medication, one should be aware of the rare but serious condition known as lactic acidosis. Lactic acidosis can result from excessive accumulation of lactic acid in the blood, which can be dangerous and sometimes life-threatening. Additionally, when taken with insulin or sulfonylureas, symptoms of hypoglycemia may occur, so careful monitoring of blood glucose changes is necessary. Patients with moderate to severe renal impairment, heart failure, acute myocardial infarction, or sepsis, and those with severely impaired liver function should not take this medication. Particularly, if a test involving iodine contrast is planned, the medication should be stopped 48 hours before the test and can be resumed only after confirming normal kidney function. This medication is not recommended for pregnant women, women who may become pregnant, or breastfeeding mothers. During treatment, irregular meals, excessive exercise, or interactions with other medications may raise the risk of hypoglycemia or lactic acidosis, so caution is needed. If severe abdominal pain indicative of acute pancreatitis occurs, immediate consultation with healthcare personnel is required. Various side effects such as gastrointestinal disorders, hypoglycemia, constipation, rash, dizziness, etc. may occur. If symptoms are severe or persistent, inform healthcare personnel. Long-term use may lead to vitamin B12 deficiency, so regular blood tests are recommended. Elderly patients may have reduced renal function, thus requiring regular kidney function tests and potential dose adjustments. In the event of overdose, immediate hospital visit for appropriate treatment is necessary, and dialysis may be required. This medication should not be used in children as its safety and efficacy have not been established. During storage, keep it out of reach of children and do not transfer it to another container. Finally, it is important to avoid alcohol while taking this medication and to regularly monitor blood glucose and kidney function, as well as consult with healthcare personnel immediately if any abnormal symptoms arise.

Side effects

severe lactic acidosis, severe hypoglycemia, hypoglycemia, constipation, positive occult blood in stool, diarrhea, gastritis, abdominal distension, abdominal pain, abdominal discomfort, elevated serum amylase, nausea, vomiting, enteritis, bloating, peptic ulcer, rash, itching, elevated ALT, elevated AST, elevated γ-GTP, dizziness, anemia, increased white blood cell count, nasopharyngitis, edema, elevated CK, positive blood in urine, elevated serum uric acid, pharyngitis, upper respiratory infection, acute pancreatitis, pseudocholinesterase, gastrointestinal symptoms, decreased serum vitamin B12 concentration, loss of appetite, drowsiness, joint pain, chest pain, headache, dyspepsia, low back pain, musculoskeletal pain, kidney stones

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to protect it from air and moisture. It is best to maintain a storage temperature between 1 and 30 degrees Celsius at room temperature to preserve its effectiveness.

Appearance and packaging

Appearance

Pale yellow oblong film-coated tablet

Package unit

30 tablets (10 tablets/PTP packaging × 3), 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.